Press Releases Year: - Any -20182017201620152014 Items per page 102550 Date Title and Summary Additional Formats Toggle SummarySep 28, 2018 Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML Toggle SummarySep 14, 2018 Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML Toggle SummaryAug 30, 2018 Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences View HTML Toggle SummaryAug 07, 2018 Alder BioPharmaceuticals® Reports Second Quarter 2018 Financial and Operating Results View HTML Toggle SummaryAug 02, 2018 Alder BioPharmaceuticals® to Present at the Canaccord Genuity 38th Annual Growth Conference View HTML Toggle SummaryJul 31, 2018 Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2018 Financial and Operating Results View HTML Toggle SummaryJun 29, 2018 Alder BioPharmaceuticals® Presents New Six-Month Data for Eptinezumab Demonstrating Improvement in Efficacy in PROMISE 2 Phase 3 Trial for Chronic Migraine View HTML Toggle SummaryJun 29, 2018 Alder BioPharmaceuticals® Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine View HTML Toggle SummaryJun 20, 2018 Alder BioPharmaceuticals® to Present New Data Further Highlighting Eptinezumab’s Efficacy Profile for Migraine Prevention at American Headache Society Meeting View HTML Toggle SummaryJun 15, 2018 Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
